Katharine Yao to Receptors, Estrogen
This is a "connection" page, showing publications Katharine Yao has written about Receptors, Estrogen.
Connection Strength
1.995
-
Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx® for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy. Ann Surg Oncol. 2019 Oct; 26(10):3232-3239.
Score: 0.587
-
Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups. Breast Cancer Res Treat. 2015 Nov; 154(1):81-8.
Score: 0.451
-
Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. Ann Surg Oncol. 2014 Oct; 21(10):3231-9.
Score: 0.416
-
Impact of Surgical Delay on Tumor Upstaging and Outcomes in Estrogen Receptor-Negative Ductal Carcinoma in Situ Patients. J Am Coll Surg. 2022 11 01; 235(5):788-798.
Score: 0.184
-
The Impact of Facility Volume on Rates of Pathologic Complete Response to Neoadjuvant Chemotherapy Used in Breast Cancer. Ann Surg Oncol. 2017 Oct; 24(11):3157-3166.
Score: 0.127
-
Surgery and hormone therapy trends in octogenarians with invasive breast cancer. Am J Surg. 2016 Mar; 211(3):541-5.
Score: 0.114
-
A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg Oncol. 2018 May; 25(5):1304-1311.
Score: 0.033
-
Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. JAMA Oncol. 2017 Jul 01; 3(7):928-935.
Score: 0.032
-
Utilization of Axillary Surgery for Patients With Ductal Carcinoma In Situ: A Report From the National Cancer Data Base. Ann Surg Oncol. 2016 10; 23(10):3337-46.
Score: 0.030
-
Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients. Ann Surg Oncol. 2012 Oct; 19(10):3257-63.
Score: 0.023